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Background: Alzheimer’s disease (AD) may present retinal changes before brain
pathology, suggesting the retina as an accessible biomarker of AD. The present work
is a diachronic study using spectral domain optical coherence tomography (SD-OCT) to
determine the total retinal thickness and retinal nerve fiber layer (RNFL) thickness in an
APPNL−F/NL−F mouse model of AD at 6, 9, 12, 15, 17, and 20 months old compared to
wild type (WT) animals.
Methods: Total retinal thickness and RNFL thickness were determined. The mean total
retinal thickness was analyzed following the Early Treatment Diabetic Retinopathy Study
sectors. RNFL was measured in six sectors of axonal ring scans around the optic nerve.
Results: In the APPNL−F/NL−F group compared toWT animals, the total retinal thickness
changes observed were the following: (i) At 6-months-old, a significant thinning in the
outer temporal sector was observed; (ii) at 15-months-old a significant thinning in the
inner temporal and in the inner and outer inferior retinal sectors was noticed; (iii) at
17-months-old, a significant thickening in the inferior and nasal sectors was found in
both inner and outer rings; and (iv) at 20-months-old, a significant thinning in the inner
ring of nasal, temporal, and inferior retina and in the outer ring of superior and temporal
retina was seen. In RNFL thickness, there was significant thinning in the global analysis
and in nasal and inner-temporal sectors at 6 months old. Thinning was also found in the
supero-temporal and nasal sectors and global value at 20 months old.
Conclusions: In the APPNL−F/NL−F AD model, the retinal thickness showed thinning,
possibly produced by neurodegeneration alternating with thickening caused by deposits
and neuroinflammation in some areas of the retina. These changes over time are
similar to those observed in the human retina and could be a biomarker for AD. The
APPNL−F/NL−F AD model may help us better understand the different retinal changes
during the progression of AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative brain pathology
characterized by a loss of neurons and their synapses, after
which an atrophy of the cerebral cortex develops (Sharma and
Singh, 2016). The main features of AD are extracellular deposits
of the protein amyloid-β (Aβ), the formation of plaques, and
intraneuronal hyper-phosphorylated tau (pTau) in the form
of neurofibrillary tangles (Ghiso et al., 2013) leading to a
neuroinflammatory process (Pan et al., 2011).
One important tissue to focus on in search of
neurodegenerative disease biomarkers is the eye. It is widely
known that patients with AD have visual problems, such as
decreased visual acuity, contrast sensitivity, color perception, and
visual integration (Salobrar-García et al., 2015a, 2016, 2019a,b).
Retinal changes have also been documented in vivo using optical
coherence tomography (OCT) both in humans (Iseri et al., 2006;
Garcia-Martin et al., 2014; Salobrar-García et al., 2015b, 2016,
2019a,b; Polo et al., 2017; Ko et al., 2018; Lad et al., 2018) and in
different AD animal models (Chiquita et al., 2019; Georgevsky
et al., 2019; Harper et al., 2020). The retinal changes observed
in the OCT results of AD patients showed macular thinning
when the disease is in an early stage, followed by thinning of
the peripapillary area when AD progresses (Garcia-Martin et al.,
2014; Salobrar-García et al., 2015b, 2019a,b; Jáñez-Escalada et al.,
2019). Retinal areas with an increased thickness were found in
AD patients, specifically in the macular area (Jáñez-Escalada
et al., 2019; Salobrar-García et al., 2019a), revealing areas of
possible gliosis prior to neurodegeneration. These changes could
be correlated with those found in the retinas of AD transgenic
models, where marked neurodegeneration and a loss of optic
nerve axons were observed (Gupta et al., 2016; Chiquita et al.,
2019; Georgevsky et al., 2019), alongside retinal thickening
and increased microglial activation in the early stages of the
disease (Perez et al., 2009; Yang et al., 2013; Gao et al., 2015;
Salobrar-García et al., 2020). In addition to the retinal structural
changes, several functional changes have been observed by
means of electroretinogram (ERG) in the APPswe/PS1 transgenic
mouse model of AD finding a significant reduction of the a and
b wave amplitudes between 12 and 16 months of age (Perez
et al., 2009). Other authors observed in this model, already
at 3 months a significant reduction of the b-wave coinciding
with the Aβ deposits in the hippocampus (Georgevsky et al.,
2019). In addition, findings, such as a slightly shortened ERG
latency in dark adapted conditions and the increased frequency
of oscillatory potentials in the old APPswe/PS1, could be related
to inadequate cholinergic innervation (Leinonen et al., 2016).
However, in this model, late-stage photopic ERG measurements
revealed that the cone mediated retinal response was preserved
in the APPswe/PS1 mice (Joly et al., 2017). Therefore, the retina
has been postulated as an accessible biomarker of AD.
Most cases of AD in humans are sporadic, and only <3%
are caused by genetic mutations (Selkoe, 2001). There is
currently no mouse model for sporadic AD (Foidl and Humpel,
2020). In recent decades, different transgenic AD models have
been generated for mice to mimic the main neuropathological
hallmarks of the disease (Foidl and Humpel, 2020), but there
is no transgenic mouse model that presents all AD features.
Most transgenic mice were made to overexpress mutant forms of
APP and/or PS1 and show the onset of Aβ age-dependent brain
deposition, gliosis, synaptic dysfunction, and memory deficits
(Duyckaerts et al., 2008). Transgenic mice that overexpress
APP have artificial phenotypes because, in addition to the Aβ,
they overproduce other APP fragments that can interfere with
intrinsic biological functions. In addition, these models use
artificial promoters that produce transgenic expression in cells
that are not always identical to those that express endogenous
APP. Another feature of APP overexpression models is the
sudden death that reflects a physiological alteration (Nilsson
et al., 2014; Saito et al., 2014). A second generation of AD mouse
models was developed to have both less artificial phenotypes
and less altered physiology (Sakakibara et al., 2018). This
alternative AD mouse models have been generated via knock-
in (KI) of a humanized Aβ sequences harboring familial AD
mutations [Swedish (NL), Beyreuther/Iberian (F), and Arctic
(G)] (Sakakibara et al., 2019). One of these second generation
ADmousemodels is the APPNL−F/NL−F that harbors the Swedish
mutation (NL) and the Iberian mutation (F). This model, unlike
the models that overexpress APP, has normal levels of full-
length APP, and its cleavage products produce a significantly
higher level of Aβ42 compared to wild type (WT) mice and
APP overexpression models, as well as exhibits a significantly
higher Aβ42/Aβ40 ratio (Saito et al., 2014). Increased Aβ42
levels in this model cause pathological deposits of Aβ in the
cerebral cortex and hippocampus, leading to infiltration of the
microglia and astrocytes surrounding the Aβ plaques starting at
6 months old (Sasaguri et al., 2017). The APPNL−F/NL−F model
reproduces several key pathologies found in AD patients. It has
been suggested that this model may be useful as a preclinical AD
mouse model to research the pathological role of amyloidosis
and amyloids related to neuroinflammation (Saito and Saido,
2018). In addition, this model presents a number of neurological
disturbances in an age-dependent manner, such as synaptic
disorders and memory impairment, in a Y-maze test (Saito et al.,
2014).
For retinal tissue, Aβ deposits have been found in several AD
models that overexpress APP (Ning et al., 2008; Shimazawa et al.,
2008; Dutescu et al., 2009; Perez et al., 2009; Koronyo-Hamaoui
et al., 2011; Gupta et al., 2016). These Aβ deposits were located in
the retinal nerve fiber layer (RNFL), ganglion cell layer (GCL),
inner plexiform layer (IPL), outer plexiform layer (OPL), and
inner nuclear layer (INL) (Ning et al., 2008; Dutescu et al., 2009;
Perez et al., 2009; Koronyo-Hamaoui et al., 2011).
Recently, the retina has been studied by OCT in transgenic
mouse models that overexpress APP, but these studies are scarce
and controversial. In an APP/PS1 model analyzing the retina
from 3 to 12 months of age, a significant decrease in retinal
thickness in the inner layers was found at 9 months of age and
in the outer layers at 12 months (Georgevsky et al., 2019). In the
3xTg-AD animal model, neurodegeneration was found to start
at 4 months-old in the innermost retinal layers. As the disease
progressed, significant changes were found in every analyzed
layer, with the exception of the ONL, where a thickening was
observed at 12 months of age (Chiquita et al., 2019), as well as a
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significant thinning of the RNFL in AD mouse retinas compared
to the WT controls (Song et al., 2020).
Despite the loss of neurons that occurs at ∼17 months-age,
for most transgenic models of AD (APP/PS1 model) (Harper
et al., 2020), diachronic studies that analyze the retinal changes
observed by OCT in AD transgenic models from early stages
to late stages of the disease could help us better understand
the retinal observations. To the best of our knowledge, there
is no study that analyzes the retina using SD-OCT in the
APPNL−F/NL−F model. Given the aforementioned advantages of
this model, the aim of this study was to analyze the changes
in retinal thickness (total retinal thickness and RNFL thickness)
over time (at 6, 9, 12, 15, 17, and 20 months of age) in a
well-validated mouse model of AD (APPNL−F/NL−F).
MATERIALS AND METHODS
Animals and Ethics
The experiments were performed on male APPNL−F/NL−F mice
produced by manipulating the mouse APP gene using a knock-in
strategy with Swedish (KM670/671NL) and Beyreuther/Iberian
(I716F) mutations, as described previously (Saito et al., 2014).
The experiments were also performed on age-matched WT
animals (C57BL/6J). The animals were obtained from the
research group led by Dr. Takaomi C. Saito at the laboratory
for Proteolytic Neuroscience, RIKEN Brain Science Institute,
Saitama, Japan.
The Aβ sequence within the mouse APP gene was humanized
and, while the Swedish mutation (NL) elevates the total amount
of Aβ40 and Aβ42, the Beyreuther/Iberian(F) mutation increases
the ratio of Aβ42/Aβ40 (Saito et al., 2014). The great advantage
of this model is that the mouse Aβ sequence is humanized and
the Swedish and Beyreuther/Iberian mutations are introduced by
knock-in technology (Saito et al., 2014). In order to accelerate
pathology and to remove murine endogenous Aβ, mutant mice
are bred in homozygosity (Sasaguri et al., 2017) explaining
why control mice are not littermates. However, this should
not be a major problem considering that mutant mice have
been backcrossed with genuine wild-type B6J mice for more
than 10 generations.
The retinas of male APPNL−F/NL−F and WT animals were
evaluated in vivo using SD-OCT at 6, 9, 12, 15, 17, and 20 months
of age.
The animals were housed in light- and temperature-controlled
rooms with a 12-h light/dark cycle and ad libitum access to food
and water in the Medical School at the University Complutense
of Madrid. Light intensity within the cages ranged from 9 to
24 lux. The SD-OCT analysis was performed under general
anesthesia induced with an intraperitoneal (ip) injection of a
mixture of ketamine (75 mg/kg; Anesketin R©, Dechra Veterinary
Products SLU, Barcelona, Spain) and medetomidine (0.26 mg/kg;
Medetor R©, Virbac España S.A., Barcelona, Spain), which can be
reversed by the antagonist atipamezole (Antisedan, 5 mg/mL;
Pfizer). During the recovery from anesthesia, the mice were
placed in their cages with a heat source to maintain their core
body temperature.
All procedures were performed in accordance with the
European Parliament, the Council Directive 2010/63/EU, and
Spanish legislation (Real Decreto 53/ 2013). The procedures
were approved by the Ethics Committee on Animal Welfare
of the University Complutense (PROEX No. 047/16) and
reported according to the Association for Research in Vision and
Ophthalmology (ARVO) statement of animal use. All procedures
minimized the number of animals used and their suffering.
Experimental Groups
Two groups of mice were used for this study: an APPNL−F/NL−F
group (n= 55) and an age-matched control (WT, n= 41) group,
as indicated inTable 1. Only the left eyes of the animals were used
in our study. This control-case study was performed at 6, 9, 12,
15, 17, and 20 months of age.
OCT Analysis
The retinal structures were evaluated using SD-OCT Spectralis
with the Heidelberg Eye Explorer software v6.13 (Heidelberg
Engineering, Heidelberg, Germany) after pupil dilation
(tropicamide 10 mg/ml; colircusi tropicamide, Alcon Healthcare,
Barcelona, Spain).
The cornea was kept moisturized using artificial tear eye
drops. To prevent a reduction in body temperature, heating pads
were placed underneath the mice.
An addition, a 25 diopter mouse lens (Heidelberg, Germany)
was added in front of the OCT camera, and the murine eye was
covered with a polymethyl methacrylate contact lens (3.2mm
diameter, base curve 1.7; Cantor&Nissel, UK), which served to
create a uniform refractive surface.
Each mouse eye was aligned with respect to the measurement
beam to ensure that the optic nerve head (ONH) was at the center
of the OCT analysis. To compensate for small eye movements,
such as those that occur as a result of respiration, motion
artifacts were minimized through real-time eye tracking in the
device software.
As in the Early Treatment Diabetic Retinopathy Study
(ETDRS), retinal thickness data were displayed as three
concentric rings 3mm in total diameter centered in the optic
nerve. These rings were distributed as follows: a central area
with a diameter of 1mm that was not considered for the
measurements, an inner ring with a diameter of 2mm, and
an outer ring with a diameter of 3mm. Both measured rings
were divided into four quadrants (superior, inferior, nasal, and
temporal) (Figures 1A,B). Due to the size of the mouse eye,
TABLE 1 | Number of mice used at different time points.
Age group APPNL-F/NL-F group (n) WT group (n)
6 months 5 7
9 months 14 6
12 months 10 7
15 months 6 7
17 months 8 7
20 months 12 7
Frontiers in Aging Neuroscience | www.frontiersin.org 3 January 2021 | Volume 12 | Article 625642
Salobrar-García et al. Retinal Changes in the APPNL−F/NL−F AD Model
FIGURE 1 | (A) Concentric rings with 1, 2, and 3mm diameters. (B) OCT section. Retinal thickness measured between the inner limiting membrane and the retinal
pigment epithelium. (C) RNFL sectors (RNFL, Retinal Nerve Fiber Layer; ST, Supero–Temporal; SN, Supero–Nasal; N, Nasal; IN, Infero–Nasal; IT, Infero-Temporal; T,
Temporal; G, Global). (D) OCT section. Result of segmentation of the OCT scan. RNFL delimited between the ILM and GCL + IPL. OCT, optical coherence
tomography; RNFL, Retinal nerve fiber layer; ILM, inner limiting membrane; GCL + IPL, ganglion cell layer and inner plexiform layer.
which differs significantly from that of the human eye, a +25
diopter optical lens was used in addition to a contact lens, so
the lateral distances were not entirely accurate. However, it was
shown that axial measurements with OCT are accurate for the
study of rodents (Dysli et al., 2015).
To analyze the RNFL, an axonal ring scan around the optic
nerve head was carried out. The RNFL was measured in six
sectors provided by the Heidelberg Software (Supero–Temporal,
Superior, Supero–Nasal, Nasal, Infero–Nasal, Temporal, Inferior,
and Temporal). The mean of all sectors is shown in the center as
the global value (G) (Figures 1C,D).
The Spectralis OCT animal software allows automatic
segmentation of the retinal layers and measurement of each
layer’s thickness through the same segmentation of the concentric
circular sectors mentioned above. After collecting the images,
if it was necessary to correct the automatic division of the
layers, manual corrections were made by the same experienced
examiner. The RNFL and total retinal thickness were then
measured. The distance between the inner limiting membrane
and the posterior surface of the RPE was defined as the total
retinal thickness.
Statistical Analysis
For the statistical analysis, we used the SPSS software 25.0 (SPSS
Inc., Inc., Chicago, IL, USA). The differences between study
groups (APPNL−F/NL−F and WT) were analyzed using a non-
parametric Mann–Whitney U Test. Data are reported as the
mean values ± standard deviation (SD). A P-value <0.05 was
considered statistically significant.
RESULTS
In this study, we evaluated the total retinal thickness and
RNFL thickness in different age groups (at 6, 9, 12, 15, 17,
and 20 months) using the APPNL−F/NL−F mouse model of
AD (APPNL−F/NL−F group) and age-matched wild-type mice
(WT group). Ninety-four mice were analyzed in total−55
APPNL−F/NL−F mice and 41 WT mice.
Total Retinal Thickness
At 6 months of age, for the APPNL−F/NL−F mice, we found
that the total retinal thickness was significantly decreased in the
temporal sector in the outer ring (244.40 ± 2.41) compared to
the WT mice (253.00 ± 6.11; p < 0.05). In this same age group,
compared to the WT mice, the remaining sectors showed slight
thinning, except for the superior sector in the inner ring, which
showed a slight thickening (without statistical significance in
both cases) (Table 2, Figure 2).
When we analyzed the 9-months-age groups, the total retinal
thickness of the APPNL−F/NL−F mice showed slight thinning
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TABLE 2 | Total retinal thickness between groups.
Total retinal thickness
Inner ring Outer ring
S I N T S I N T
6 months APPNL−F/NL−F Mean 250.60 244.20 241.40 243.00 254.20 243.80 246.20 244.40
SD 5.73 4.82 4.28 4.53 6.38 4.44 5.63 2.41
WT Mean 249.43 249.43 246.00 247.43 256.57 253.57 248.86 253.00
SD 6.02 7.30 4.28 7.25 8.28 9.11 6.18 6.11
P-value 0.935 0.255 0.101 0.221 0.684 0.061 0.624 0.028*
9 months APPNL−F/NL−F Mean 252.36 247.29 247.43 247.57 257.71 245.36 251.21 246.14
SD 8.42 7.24 5.26 5.56 6.78 9.43 4.51 6.68
WT Mean 257.17 250.33 250.50 251.83 261.67 249.00 248.17 252.33
SD 7.31 6.12 6.92 7.68 11.38 5.37 7.36 7.12
P-value 0.246 0.342 0.230 0.185 0.282 0.535 0.320 0.063
12 months APPNL−F/NL−F Mean 253.00 246.56 245.56 246.33 257.22 246.11 247.67 246.22
SD 8.38 3.17 5.96 5.70 11.29 4.86 4.85 7.07
WT Mean 255.86 252.86 249.71 250.71 258.14 252.57 250.14 250.57
SD 6.94 7.84 7.04 6.92 6.31 7.61 6.87 5.53
P-value 0.366 0.089 0.202 0.123 0.560 0.100 0.243 0.110
15 months APPNL−F/NL−F Mean 253.83 248.00 244.83 249.17 257.50 247.00 248.17 247.67
SD 4.96 7.90 2.48 8.64 9.12 7.75 4.36 9.58
WT Mean 252.71 254.86 251.00 250.57 257.29 255.29 250.71 251.57
SD 7.11 5.90 6.68 8.48 9.23 6.34 6.05 6.11
P-value 0.429 0.044* 0.031* 0.473 0.617 0.038* 0.418 0.195
17 months APPNL−F/NL−F Mean 255.38 250.25 251.63 248.25 257.75 252.88 255.00 248.13
SD 7.48 4.37 5.73 3.37 9.10 5.30 7.48 4.52
WT Mean 252.29 244.71 243.00 246.71 255.00 245.00 243.71 249.71
SD 4.68 4.57 4.73 3.20 8.50 5.45 3.30 4.68
P-value 0.450 0.036* 0.024* 0.415 0.602 0.023* 0.004** 0.523
20 months APPNL−F/NL−F Mean 240.83 241.83 239.08 240.25 245.25 244.91 242.58 241.67
SD 6.86 4.53 5.74 4.75 8.67 7.49 7.14 6.96
WT Mean 250.67 253.17 251.50 251.50 255.33 252.33 249.50 252.00
SD 9.87 8.38 8.89 8.80 9.54 8.14 6.75 9.61
P-value 0.054 0.007** 0.009** 0.007** 0.039 0.076 0.100 0.031
* in bold: p-value <0.05; **in bold: p-value <0.01; Mann-Whitney U Test; WT, wild type; SD, standard deviation; S, superior; I, inferior; N, nasal; T, temporal.
without statistical significance in all sectors, except for the nasal
sector in the outer ring, which was slightly thickened compared
to the WT group (Table 2, Figure 2).
At 12 months of age, total retinal thickness in the
APPNL−F/NL−F group showed no statistically significant changes
in comparison to the WT group. However, at 12 months
old, all sectors showed slight thinning, with the inferior
sectors in both the inner and outer rings being the thinnest
(Table 2, Figure 2).
At 15 months of age, the total retinal thickness of the
APPNL−F/NL−F mice group showed a significant decrease in the
inferior sector in both the inner (248.00 ± 7.90) and outer ring
(247 ± 7.75) and in the inner ring of the nasal sector (244.83
± 2.48) compared to the WT group (254.86 ± 5.90, 255.29 ±
6.34, and 251 ± 4.73, respectively p < 0.05 in all cases). In
this age group, the remaining sectors showed slight thinning,
except for the superior sector in the inner ring, which showed
a slight thickening (without statistical significance in both cases),
in comparison to the WT mice group (Table 2, Figure 2).
At 17 months of age, in the APPNL−F/NL−F group compared
to the WT group, we found a significant increase in thickness in
the nasal and inferior sectors in the inner and outer rings. The
nasal sectors in both the inner ring (251.63± 5.73 vs. 243± 4.73,
for APPNL−F/NL−F and WT groups, respectively) and the outer
ring (255.00± 7.48 vs. 243.71± 3.30, for APPNL−F/NL−F andWT
groups, respectively) were significantly thicker (p< 0.05 for inner
ring and p < 0.01 for outer ring) in the APPNL−F/NL−F group
compared to the WT group. Similarly, in the APPNL−F/NL−F
group, the inferior sectors in both the inner ring (250.25 ±
4.37 vs. 244.71 ± 4.57, for APPNL−F/NL−F and WT groups,
respectively) and the outer ring (252.88 ± 5.30 vs. 245.00 ±
5.45, for APPNL−F/NL−F and WT groups, respectively) showed
statistically significant thickening compared to the WT group (p
< 0.05 in all cases; Table 2, Figure 2).
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FIGURE 2 | Colorimetric differences of retinal thickness in each age group between the APPNL−F/NL−F and WT animal groups. OCT rings with 1, 2, and 3mm
diameters. Red: thickening; blue: thinning. APPNL−F/NL−F, Single App Knock-in mouse model of Alzheimer’s disease; WT, Wild type; OCT, optical coherence
tomography; N, nasal; T, temporal.
When we compared the APPNL−F/NL−F group with the WT
control group in the oldest animals (20 months), we found a
significant thickness decrease in the inner and outer ring in
the temporal sector (p < 0.01 and p < 0.05, respectively), in
the inner ring of both inferior and nasal sectors (p < 0.01 in
both cases) and in the outer ring of the superior sector (p <
0.05). In the APPNL−F/NL−F mice in comparison with the WT
group: the temporal sectors showed a statistically significant
decrease in both the inner ring (240.25 ± 4.75 vs. 251.50 ±
8.80, in APPNL−F/NL−F and WT, respectively) and in the outer
ring (241.67 ± 6.96 vs. 252.00 ± 9.61, in APPNL−F/NL−F and
WT, respectively); both the nasal sectors and inferior sectors
showed statistically significant thinning in the inner ring (239.08
± 5.74 vs. 251.50 ± 8.89 for nasal sector and 241.83 ± 4.53
vs. 253.17 ± 8.38 for inferior sector, in APPNL−F/NL−F and
WT, respectively) and the superior sectors showed statistically
significant thinning, in the outer ring (245.25 ± 8.67 vs.
255.00± 9.54, in APPNL−F/NL−F and WT, respectively) (Table 2,
Figure 2).
RNFL Thickness
Overall, in RNFL, there were no statistically significant changes
over time observed in our study, except at 6 and 12 months of
age. At early time point in the APPNL−F/NL−F group, we found
a significant thickness decrease compared to the WT group in
the nasal sector (21.80± 1.48 vs. 24.29± 1.80, in APPNL−F/NL−F
and WT, respectively), in the infero–temporal sector (21.20 ±
1.30 vs. 25.57 ± 4.58, in APPNL−F/NL−F and WT, respectively),
and in the global value (23.00 ± 1.00 vs. 26.71 ± 4.46, in
APPNL−F/NL−F and WT, respectively; p < 0.05 in all cases)
(Table 3, Figure 3).
At 9 months-old, the thickness of all sectors in the
APPNL−F/NL−F group slightly decreased compared to the WT
group without statistical significance (Table 3, Figure 3).
By contrast, at 12 and 15 months of age, in the APPNL−F/NL−F
group, only four sectors showed a slight non-significant thickness
decrease (in the supero–temporal, temporal, nasal, and infero–
nasal sectors), and the remaining two sectors were slightly
thickened without statistical significance (supero–nasal, and
infero–temporal) compared to theWT group (Table 3, Figure 3).
When comparing APPNL−F/NL−F and WT mice at 17 months
old, it was found that the RNFL thickness of all sectors
increased slightly without statistical significance, except in the
supero–temporal sector, where we found a slight non-significant
thickness decrease (Table 3, Figure 3).
By contrast, at 20 months of age, the highest age in the
APPNL−F/NL−F group, we found a significant thickness decrease
in comparison to WT group in the nasal sector (24.83 ± 2.33
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TABLE 3 | Retinal nerve fiber layer thickness between groups.
Retinal nerve fiber layer thickness
N T SN ST IN IT G
6 months APPNL−F/NL−F Mean 21.80 23.60 25.60 25.00 24.80 21.20 23.00
SD 1.48 0.89 4.16 2.12 1.30 1.30 1.00
WT Mean 24.29 25.86 24.00 28.86 25.71 25.57 26.71
SD 1.80 2.19 3.00 4.06 4.46 4.58 4.46
P-value 0.030* 0.062 0.741 0.087 0.868 0.014* 0.039*
9 months APPNL−F/NL−F Mean 24.29 26.36 24.64 27.00 25.57 23.86 25.29
SD 2.73 3.46 4.09 4.71 6.28 3.63 2.61
WT Mean 26.17 28.00 24.50 27.83 29.00 24.50 26.67
SD 2.14 2.37 2.95 2.64 2.37 2.43 1.75
P-value 0.133 0.213 0.708 0.868 0.299 0.617 0.170
12 months APPNL−F/NL−F Mean 25.40 25.90 25.70 27.60 25.00 25.90 26.00
SD 2.07 2.28 3.37 2.59 5.42 3.14 1.70
WT Mean 26.33 25.50 23.83 27.83 28.50 23.67 26.17
SD 1.63 2.17 3.25 2.99 2.95 2.58 1.47
P-value 0.352 0.659 0.414 0.869 0.190 0.272 0.868
15 months APPNL−F/NL−F Mean 24.50 25.67 25.33 26.17 28.17 25.17 25.50
SD 3.62 1.97 3.39 4.07 4.36 2.14 2.43
WT Mean 27.29 26.86 26.14 29.00 29.71 25.29 27.14
SD 3.99 3.72 3.02 5.03 2.87 5.59 2.91
P-value 0.311 0.718 0.829 0.194 0.251 0.665 0.348
17 months APPNL−F/NL−F Mean 26.75 27.25 28.00 26.38 30.00 26.38 27.25
SD 4.30 5.39 3.25 3.85 5.55 3.29 3.06
WT Mean 26.29 26.29 25.71 28.43 26.71 23.43 26.29
SD 1.98 3.99 3.25 7.55 4.46 2.70 2.29
P-value 0.861 0.861 0.244 0.636 0.270 0.077 0.481
20 months APPNL−F/NL−F Mean 24.83 24.58 25.25 26.33 24.83 24.17 24.67
SD 2.33 3.73 3.47 4.08 5.56 4.84 2.06
WT Mean 30.33 27.00 28.00 31.50 29.17 28.33 29.00
SD 1.86 4.52 4.86 2.35 5.42 3.44 1.79
P-value 0.001* 0.257 0.343 0.011* 0.158 0.081 0.002*
* in bold: p-value <0.05, Mann-Whitney U Test; WT, wild type; SD, standard deviation; N, nasal; T, temporal; SN, supero-nasal; ST, supero-temporal; IN, ínfero-nasal; IT, ínfero-temporal;
G, mean global thickness.
vs. 30.33 ± 1.86, in APPNL−F/NL−F and WT, respectively), in
the supero-temporal sector (26.33 ± 4.08 vs. 31.50 ± 2.35, in
APPNL−F/NL−F and WT, respectively), and in the global value
(24.67 ± 2.06 vs. 29.00 ± 1.79, in APPNL−F/NL−F and WT,
respectively) (Table 3, Figure 3).
DISCUSSION
The present work is the first diachronic SD-OCT study of the
RNFL thickness and total retinal thickness in APPNL−F/NL−F
mice at 6, 9, 12, 15, 17, and 20 months of age compared with
WT animals. In this way, the development of the retinas could
be tracked as the disease progressed. This diachronic study
covers a wider timeframe than any other study performed so
far. Histological studies provide a wide spectrum of information,
but the processing of retinal tissue for analysis causes thicknesses
to vary, which makes it difficult to correlate directly with
the data provided by current techniques like OCT, which
allows us to analyze in vivo the changes experienced by the
retina as the disease develops (Salobrar-García et al., 2016).
In this study we demonstrated for the first time retinal
changes from the early to late stages of AD using OCT in
the APPNL−F/NL−F model.
The APPNL−F/NL−F model presents an age-related Aβ
pathology, memory deterioration, behavioral problems, and
neuroinflammation (Cash et al., 2013; Rochat et al., 2013; Saito
et al., 2014; Masuda et al., 2016; Sasaguri et al., 2017; Shah et al.,
2018) and allows us to estimate early changes in the retina.
It is now known that there are relationships between certain
areas of the brain and the retina. Specifically, the thickness
of peripapillary RNFL (pRNFL) in the temporal sector is
related to the volume of the medial temporal lobes, especially
with the volume of the hippocampus (Shi et al., 2020). In
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FIGURE 3 | Colorimetric differences of RNFL thickness at each time point between the APPNL−F/NL−F and WT groups. OCT sectors. Red: thickening; blue: thinning.
APPNL−F/NL−F, Single App Knock-in mouse model of Alzheimer’s disease; WT, Wild type; RNFL, Retinal nerve fiber layer; N, nasal; SN, Supero–Nasal; ST,
Supero–Temporal; T, temporal; IT, Infero-Temporal; IN, Infero–Nasal; G, global.
the lower sector the pRNFL thickness is associated with the
volume of the occipital lobes and selectively with the volume
of the lingual gyrus. Therefore, the cerebral changes observed
in AD may be related to retinal changes and the retina
may be useful as a biomarker of neurodegenerative diseases
(Shi et al., 2020).
In APPNL−F/NL−F model, at 3 months old, there was no
presence of Aβ pathology, although there was already an
alteration of the proteome in both the hippocampus and the
cortex compared to WT mice. The early increase in Tris-soluble
Aβ42 levels suggests that the pre-symptomatic stages of AD begin
before amyloidosis Aβ (Schedin-Weiss et al., 2020). In addition,
the accumulation of Aβ is age-dependent from 1 to 18 months
(Petrache et al., 2019). Aβ brain deposits have been reported at 6
months of age in this AD model (Saito et al., 2014), developing
first in the hippocampus and then becoming more significant in
the cerebral cortex (Schedin-Weiss et al., 2020). At 9 months old,
there was a significant amount of Aβ plaques in the parenchymal
brain, with the Aβ plaque load reaching its maximum at 18
months (Schedin-Weiss et al., 2020). While the brain changes in
this model have been studied, there are not works analyzing the
retina. However, in other transgenic models retinal changes have
been previously reported.
In the retina, the formation of Aβ plaques was described to
occur at 6 months in the APP/PS1 model (Georgevsky et al.,
2019), although other authors observed these plaques earlier in
the retina at 2.5 months old (Koronyo-Hamaoui et al., 2011).
Using the 3xTg-AD model, it was demonstrated that there is a
positive correlation between retinal thickness and the volume of
the visual cortex (Chiquita et al., 2019), as well as the behavior
of the microglia in the retina, showing activation and migration
between the different layers of the retina in whole-mount retinas
(Salobrar-García et al., 2020). Histological alterations has been
described in the retina, such as a decrease in the density of retinal
ganglion cells and the nerve fiber layer, thinning of the inner
plexiform layer, and the presence of Aβ plaques in the inner
nuclear layer in a APP/PS1 model (Gupta et al., 2016).
Scarce studies have analyzed retinal changes using OCT in
transgenic models (APP/PS1 and 3xTg-AD), however, to our
knowledge, there is no study that analyses the retina in the
APPNL−F/NL−F model. By analyzing two horizontal lines above
and below the optic nerve, Georgevsky et al. (2019) showed, in
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both APP/PS1 mice and WT controls, a significant age-related
reduction in the inner retinal thickness from 3 to 12months, with
a significant difference between the APP/PS1 and WT mice in
both the inner and outer retinal thickness starting at 9 months.
In contrast, Harper et al. (2020) using multicontrast OCT, more
recently found no significant changes in retinal thickness between
APP/PS1 mice and control mice in any of the retinal regions
analyzed by scanning an annulus around the ONH divided
into two sectors. Finally, Song et al. (2020) using a multimodal
imaging system with co-registered OCT and angle-resolved low-
coherence interferometry, found a significant thinning of RNFL
in 3xTg-AD mouse retinas compared to the WT controls.
Although the use of OCT gives us in vivo images at a very
high resolution that allow us to analyze the retinal layers in
animal model studies, most OCTs designed for animal studies
have no tracker system. To date, no published studies have been
conducted using this technique (Georgevsky et al., 2019; Harper
et al., 2020). However, our diachronic study in APPNL−F/NL−F
model was conducted using SD-OCT with a tracking system that
allowed us to re-examine the exact same area, thereby avoiding
measurement errors or unintentional movements and giving us
the ability to analyse areas of the retina that cover almost the
entire posterior pole instead of a single scan line.
In APPNL−F/NL−F mice the early retinal thinning observed
with SD-OCT at 6 months of age (which was significant in total
retinal thickness only in the outer temporal sector, as well as in
the nasal, infero–temporal sectors and mean global value of the
RNFL) appeared to develop toward more significant thinning
by the final time point. It is possible that these initial changes
are the consequence of the progressive accumulation of soluble
oligomers of Aβ (in our model Tris-soluble Aβ42), inducing early
neuronal dysfunction due to their toxicity. These changes are
in line with the observation that the APOE ε4 genotype of AD
is associated with a decrease in GABAergic interneurons and
glutamatergic signaling in the hippocampus, which is a risk factor
for AD (Andrews-Zwilling et al., 2010; Busche and Konnerth,
2016; Shah et al., 2018). In the APP/PS1 model, primary visual
cortex degeneration has also been observed in parallel with an
increase in Aβ plaque with age. This is specific to the hyperactive
neurons located near plaques, which are also found in the frontal
cortex in AD (Busche et al., 2008). The hyperactive astrocytes
located in the vicinity of the Aβ plaques that are formed may also
contribute to neuronal protection, which can directly improve
neuronal activity initially. This astrogliosis becomes noticeable
very early and correlates with the slow development of AD in
the APPNL−F/NL−F mice at 6 months (Saito et al., 2014; Petrache
et al., 2019). The findings at this early time may also be secondary
to the astrocyte reduction of glutamate synaptic recapture (Li
et al., 2009) and to the excessive amount of Aβ dimers, as
well as the Aβ1−40 monomers and dimers, which increase the
presynaptic release of glutamate (Fogel et al., 2014). Therefore,
a combination of both causes could increase residual glutamate
levels, thereby promoting neuronal hyperactivity, which is a
precursor to plaque formation (Busche and Konnerth, 2016;
Schedin-Weiss et al., 2020).
In the APPNL−F/NL−F mice, the time between 9 and 15months
of age was characterized by a slow and progressive tendency
toward thickening of the retina with alternation of thinned
retinal sectors, which vary over time and present only statistical
significance at 15 months in some sectors of the total retinal
thickness (outer and inner rings of inferior sector and inner ring
of the temporal sector). These changes could correlate to the
brain changes seen in this model at 9 months, when neuronal
death was detected by necrosis in the cerebral cortex (Schedin-
Weiss et al., 2020). At the same time, the effect of microgliosis
and astrogliosis are significant in the APPNL−F/NL−F model
in the cortex, hippocampus, and subcortical region compared
to the WT mice (Masuda et al., 2016). These mechanisms
could explain why, at 9 months, although there were changes
in the OCT analysis in the APPNL−F/NL−F group compared
to WT mice, these changes were not statistically significant
since neuroinflammation could appears at the same time as
neurodegeneration, masking the changes seen at 6 months of
age (Saito et al., 2014; Masuda et al., 2016). These slow and
minor changes in retinal thickness, which evolve steadily until
15 months of age, could be produced by the progressive deposit
of Aβ plaques (Radde et al., 2006; Ferguson et al., 2013; Nilsson
et al., 2014; Masuda et al., 2016; Stevanovic et al., 2017; Shah
et al., 2018; Petrache et al., 2019; Schedin-Weiss et al., 2020)
and by the mechanisms of inflammation, phagocytosis, and
microglial migration between different retinal layers (Lee et al.,
2020; Salobrar-García et al., 2020).
While in the APP/PS1 model, at 16 months of age, there was
a heavy plaque burden throughout all cortical regions (Ferguson
et al., 2013), as well as increased microglial activity (Perez et al.,
2009), in the murine model used in our study, this heavy plaque
load peaked at 18 months. At the same time, the mice showed
alterations in different proteins of the hippocampus and the
cortex, which are involved in various neuronal maintenance
activities (Schedin-Weiss et al., 2020).
These findings may be linked to the overall increase in total
retinal thickness at 17 months of age in the APPNL−F/NL−F
group, with significance in the nasal and inferior sectors,
the inner and outer sectors, and the RNFL (albeit without
statistical significance); these changes were more noticeable
in the nasal–superior, nasal–inferior, and temporal–inferior
sectors. At this point in our study, where the greatest
thickening was observed, we precisely observed that Aβ brain
plaques accumulate at an accelerated rate (Koronyo-Hamaoui
et al., 2011), which coincides with the findings of our model
(Saito et al., 2014; Schedin-Weiss et al., 2020).
In addition, astrocytes are hyperreactive, surrounding the
Aβ plaques and releasing proinflammatory factors that induce
higher microglial activation (Saito et al., 2014; Busche and
Konnerth, 2016; Masuda et al., 2016; Shah et al., 2018). In
the APP/PS1model there was an increase in the microglial
marker F4/80, inflammatory cytokine MCP-1, and TUNNEL-
positive cells in the RGC layer (Ning et al., 2008). In addition,
the activated microglia may trigger a neuroinflammatory
response (Perez et al., 2009) that could contribute to retinal
disorganization, as demonstrated by the functional alterations
present in the electroretinogram of the APP/PS1 mouse
model (Krasodomska et al., 2010; Ramirez et al., 2017). In
APPNL−F/NL−F mice, high levels of Aβ42 cause pathological Aβ
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deposits in the cerebral cortex and hippocampus, which are
accompanied by increased neuroinflammation, with activation
of the astrocytes and microglia surrounding the plaques from 6
months of age (Saito et al., 2014; Sasaguri et al., 2017; Schedin-
Weiss et al., 2020). In our study, Iba-1+ cells located in the
OPL and IPL were larger, with thicker and larger somas and
processes than in the WT group (Supplementary Figures 1D,F).
In addition, in the GCL-NFL the Iba-1+ cells had a more
amoeboid appearance with thicker somas and retracted processes
(Supplementary Figures 1D,F). In the APPNL−F/NL−F group
there was an increase in GFAP+ immunostaining with astrocytes
accumulating in areas where Iba-1+ cells also clustered
(Supplementary Figures 1E,F). When the microglia is activated,
it undergoes morphological changes and it is transformed into
cells with an amoeboid appearance and phagocytic properties,
capable of releasing substances that induce an inflammatory
response (Rowland and Shneider, 2001). These morphological
changes are gradual, ranging from the branched resting state
to an intermediate, early activated or “primed” state, and
finally reaching the amoeboid phagocytic state (Perry, 2004).
In the “primed” state, the microglia increases its vigilance state
and shows a thickening of the cell body and its processes.
This change in the microglia can occur in response to
primary factors derived from neurons or astrocytes. Astrogliosis
has also been observed in patients with AD in the GCL
(Grimaldi et al., 2018, 2019). All microglial and astroglial cell
changes, which may be associated with the neuroinflammatory
process, could result in the increased retinal thickness observed
in APPNL−F/NL−F group.
Finally, at 20 months of age, which is the latest time point
we analyzed, the findings of SD-OCT show significant thinning
of the total retina thickness in the inner ring of nasal, inferior
and temporal sectors and in the outer rings of superior and
temporal sectors, contrary to where the thickening occurred at
17 months, which could be the result of the generalized thinning
of the retina. It should be noted that the outer temporal sector,
the first sector with a significant change at 6 months, again
showed significant thinning being more pronounced than that
at earlier time points. The RNFL showed generalized thinning
reaching statistical significance in nasal, supero-temporal sectors
and mean global value. This situation could be a consequence
of the neurodegeneration caused by high levels of Aβ and
oligomers, which could be promoting neurotoxicity at this
time point (Schedin-Weiss et al., 2020). At the same time,
a decrease in retinal ganglion cell density due to apoptosis
(Ning et al., 2008; Gupta et al., 2016), a decrease in the
axon density of the optic nerve, and a significant thinning of
the inner plexiform layer were found in the APP/PS1 model
(Gupta et al., 2016).
Notably, in the SD-OCT analysis from 6 to 20 months of age,
in the RNFL, the only sector that did not increase in thickness
was the superior temporal sector, while that with the most
fluctuations was the superio–nasal sector, which correlates with
the temporal sectors in total retinal thickness because, again,
the sector that exhibited the least thickness variation was the
outer temporal sector. These structural changes are consistent
with the functional findings of the electroretinogram (ERG),
which show dysfunction of the RGCs and cones, as well as a
response from bipolar and other interneuronal cells in the inner
retina in the APP/PS1 mice (Gupta et al., 2016), which could
support the diminished thickness of the retina detected in our
APPNL−F/NL−F mice.
It must be considered that this data should be corroborate
in future works with molecular biological investigations that
confirm the findings in this model.
In summary, the first changes observed at 6 months of age
included a significant thinning of the total retinal thickness in the
outer temporal sector, and significant thinning of the RNFL in the
nasal and inferior–temporal sectors, and mean global value. At
the later time points, which correspond to 9 and 12months of age,
there was a slow and progressive evolution toward thickening,
with alternation of the thinned sectors, albeit without statistical
significance. At 15 months of age, there was a significant thinning
of the total retinal thickness in the inner rings of temporal and
inferior sectors and in the outer ring of inferior sector. At 17
months of age there were a widespread thickening of the total
retina, which was significant in the inferior and nasal sectors
of both the inner and outer ring. This thickening could be due
to a neuroinflammatory process produced by astrocytes and
microglia changes. Finally, at 20 months of age, the SD-OCT
showed generalized non-significant thinning of the RNFL and a
considerable thinning of the total retinal thickness, with greatest
significance in the superior and temporal sectors of both the inner
and outer ring.
CONCLUSIONS
In conclusion, this diachronic study of the murine model
of APPNL−F/NL−F of AD from 6 to 20 months of age
provides significant information on the variations in total retinal
thickness and RNFL measured by SD-OCT. In this model,
the retinal thickness showed thinning, possibly produced by
neurodegeneration alternating with thickening that could be
caused by deposits and neuroinflammation in some areas of
the retina.
Retinal changes over time, similar to those observed in the
human retina could be a biomarker for AD. The APPNL−F/NL−F
AD model may help us better understand the different retinal
changes during the progression of AD.
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